Johnson & Johnson vaccine delayed in Europe due to safety concerns
Johnson and Johnson has delayed the rollout of its Covid vaccine in Europe after regulators in the United States called for a pause because of safety concerns.
The vaccine is marketed under the brand name Janssen in Europe.
Six people who'd had the vaccine in the US have developed rare and severe blood clots. It's so far been given to around seven million Americans.
Six people who'd had the vaccine in the US have developed rare and severe blood clots. It's so far been given to around seven million Americans.
